BioInvent International
LUND, SWEDEN / ACCESSWIRE / October 28, 2021 / BioInvent International (STO:BINV)
"The powerful combination of BioInvent's R&D and in-house manufacturing provides invaluable support to our clinical development and facilitates the execution of our current clinical portfolio. The integration of functions, on top of world leading science, makes it possible for us to develop novel treatments for patients suffering from serious diseases. The solid balance sheet and strong, loyal shareholders support us in achieving our goals," said Martin Welschof, BioInvent CEO.
Events in the quarter
• (R) BioInvent announced a second clinical trial collaboration and supply agreement with Merck to evaluate BI-1808 in combination with Keytruda® (pembrolizumab) in patients with advanced solid tumors.
• Emma Meurling joined Bioinvent as Human Resource (HR) Director.
Events after the period
• BioInvent and Transgene announced that preclinical data for BT-001, a novel oncolytic virus delivering an anti-CTLA-4 antibody for the treatment of solid tumors, will be presented at SITC in November 2021.
• New data on the lead drug candidate BI-1206 Phase 1/2a study in non-Hodgkin's lymphoma (NHL) to be presented at the ASH (American Society of Hematology) conference December 11-14.
• New production agreement with CRUK to produce additional batch of anti-HER3 antibody.
• Prof. Eggermont new member of the BioInvent Scientific Advisory Board.
Financial information
Third quarter 2021
• Net sales SEK 3.0 (16.3) million.
• Loss after tax SEK -62.6 (-32.9) million.
• Loss after tax per share before and after dilution SEK -1.07 (-1.00).
• Cash flow from operating activities -57.5 (-31.4) million.
January - September 2021
• Net sales SEK 14.5 (48.6) million.
• Loss after tax SEK -199.7 (-104.9) million.
• Loss after tax per share before and after dilution SEK -3.79 (-4.00).
• Cash flow from operating activities SEK -170.1 (-91.8) million.
• Liquid funds and long-term investments as of September 30, 2021: SEK 1,445.3 (642.1) million.
The complete report is attached as pdf and is available on the company's website www.bioinvent.com/investors/#financialreports.
(R)= Regulatory event
Contacts
Cecilia Hofvander
Senior Director Investor Relations
Tel: +46 46 286 85 50
Email. cecilia.hofvander@bioinvent.com
About Us
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow us on Twitter: @BioInvent.
Attachments
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/670065/BioInvent-International-AB-Interim-Report-January--September-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Pet-Food Revolution: Two New Global Surveys Reveal Growing Guardian Openness to Sustainable Diets for Dogs and Cats14.11.2025 15:05:00 CET | Press release
LONDON, UK / ACCESS Newswire / November 14, 2025 / Two pioneering studies published in the journal Animals have explored in depth how dog and cat guardians perceive more sustainable pet food options. Led by Jenny L. Mace, Alexander Bauer, Andrew Knight and Billy Nicholles, the research sheds new light on the potential for alternative proteins and plant-based diets in the companion animal sector. Study 1 - Dogs: ‘Consumer Acceptance of Sustainable Dog Diets: A Survey of 2,639 Dog Guardians' In the first study, the team surveyed 2,639 dog guardians worldwide. Around 84% of respondents were currently feeding their dogs either conventional or raw meat-based diets. However, a substantial 43% of this group reported they would nevertheless consider at least one type of more sustainable dog food (such as vegan, vegetarian or cultivated-meat formulations). Among the alternative options, the most acceptable was cultivated meat-based dog food (chosen by 24% of these respondents), compared to vege
Kraft Heinz and OMP Showcase Smarter, More Sustainable Value Chain at Gartner Supply Chain Planning Summit13.11.2025 15:00:00 CET | Press release
ATLANTA, GEORGIA / ACCESS Newswire / November 13, 2025 / OMP, a leader in supply chain planning solutions, is showcasing how Kraft Heinz is transforming its global food supply chain at the Gartner Supply Chain Planning Summit 2025 in Denver. The leading food and beverage company will share how it is driving efficiency from farm to table with OMP's Unison Planning™. By leveraging autonomous planning, decision intelligence, and AI optimization, Kraft Heinz enhances collaboration, manages complexity, and reduces waste. Kraft Heinz's journey to a smarter, more sustainable value chain Thiago Serra, Head of Integrated Business Planning at Kraft Heinz, will discuss how smart, data-driven planning is helping the company build a more agile and sustainable value chain. Gain insights into how Kraft Heinz combines digital intelligence and end-to-end visibility to create real business impact across operations. Explore human-AI synergy at the OMP booth The Gartner Supply Chain Planning Summit, takin
Preservica Integrates Active Digital Preservation with Microsoft 365 Archive12.11.2025 15:00:00 CET | Press release
BOSTON, MA AND OXFORD, UK / ACCESS Newswire / November 12, 2025 / Preservica is expanding its ongoing collaboration with Microsoft with a new integration to bring embedded Active Digital Preservation™ to Microsoft 365 Archive. The latest Preserve365® integration offers Microsoft customers additional flexibility and control over the management of long-term SharePoint content. With Preservica's embedded Active Digital Preservation software, IT and Information Governance (IG) teams can now seamlessly archive and actively preserve high-value SharePoint sites - such as completed projects containing long-term regulatory, legal, or operational data. This protects critical data from obsolescence, ensuring long-term records are always immediately accessible in trusted, readable formats to enable business teams to respond quickly and confidently to audits, legal proceedings, maintenance continuity and AI-driven initiatives. Better together: Optimizing cost and compliance for long-term content. M
Karbon-X and Hockey Canada Partner to Make Sustainability Part of Canada's Game12.11.2025 15:00:00 CET | Press release
The Canadian-based climate-solutions company joins forces with Hockey Canada to deliver measurable sustainability impact across national tournaments and community programs. CALGARY, AB / ACCESS Newswire / November 12, 2025 / Following Hockey Canada's announcement earlier this week, Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company") is proud to confirm its new partnership with Hockey Canada, becoming the organization's Official Sustainability Partner and advancing verified sustainability initiatives across one of the nation's most celebrated sports. The multi-year partnership integrates verified, measurable sustainability programs into Hockey Canada's national tournaments and grassroots registration, empowering players, fans, and communities across the country to take part in meaningful environmental initiatives. Together, the two organizations are uniting national pride with environmental purpose, showing that every game can leave a positive impact. Through the partnership, sele
Loar Holdings Inc. Reports Q3 2025 Record Results and Upward Revisions to 2025 Outlook and Full Year 2026 Outlook12.11.2025 14:30:00 CET | Press release
WHITE PLAINS, NY / ACCESS Newswire / November 12, 2025 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our"), reports record results for the third quarter of 2025, upward revisions to 2025 outlook, and full year 2026 outlook. "The strong tailwinds of secular growth in commercial passenger traffic, immense backlogs at the airframe manufacturers, and global demand for defense products once again led us to a record quarter," stated Dirkson Charles, Loar CEO and Executive Co-Chairman of the Board of Directors. Third Quarter 2025 Net sales of $126.8 million, up 22.4% compared to the prior year's quarter. Net income of $27.6 million, up 218.9% compared to the prior year's quarter. Diluted earnings per share of $0.29, up 222.2% compared to the prior year's quarter. Adjusted EBITDA of $49.1 million, up 28.9% compared to the prior year's quarter. Net income margin for the quarter improved to 21.8% compared to the prior year's quarter of 8.4%. Adjusted EBITDA Margin for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom